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The past few decades have seen an explosion of research activities aimed at understanding the fundamental molecular mechanisms of human diseases. However, our comprehension of clinical disease processes has largely lagged behind. Indeed, many of the molecular pathways thought to be crucial in connecting various disease processes still have unknown clinical impli cations. For these reasons, the Precision Medicine Initiative was launched with efforts both to link molecu lar data with clinical disease phenotypes, and to iden tify precise patient subpopulations that differ in their disease susceptibility, progression, and prognosis so that patientspecific treatments can be implemented 1, 2 . Human induced pluripotent stem cell (hiPSC) technol ogy, one of several promising techniques involved in this initiative, offers a unique platform by which human diseases with their underlying genetic and epigenetic contributions can be modelled in cell culture [3] [4] [5] [6] [7] (FIG. 1) .
Using this technology, drugs can be screened against patients' complex genetic backgrounds to yield infor mation regarding patientspecific cardiotoxicity [8] [9] [10] . In this Review, we describe how hiPSCs can have an important role in precision medicine. The technical advances in hiPSC research and various clinically rele vant applications of hiPSCs will also be discussed, with particular emphasis on disease modelling and drug discovery. With further refinement, hiPSC technology will shape the future of cardiovascular research and contribute to the clinical practice of cardiovascular precision medicine.
Role of hiPSCs in precision medicine
The fundamental goal of the Precision Medicine Initiative is to develop prevention and treatment strat egies that take into account individual variability 1 . The underlying assumption of this approach is that differ ences in patients' genetic makeup and environmental exposure contribute to their differential clinical out comes. Indeed, a growing body of research has shown that differences at the genetic level can be characterized by genome sequencing and used to guide clinical deci sions. For example, a male patient aged 4 years survived a lifethreatening gut inflammation after his doctors found a mutation known to cause immune dysregula tion by wholeexome sequencing and, accordingly, per formed a cord blood transplantation to save his life 11 . The strong push for more widespread use of whole genome sequencing makes practical sense, as both the rate of increase in the speed of genome sequencing and the rate of decline in its cost since 2007 easily surpass Moore's law -a projection in the computer industry describing the doubling of growth (for example, number of transistors in an integrated circuit) every 2 years 12 . However, does DNA alone predict disease?
Studies from monozygotic twins have shown that despite similar height and appearance, they do not always develop or die from the same diseases 13 . Numerous studies have found that genetics alone might not be better than traditional risk factors for predicting a person's risk of developing most diseases, especially for diseases that are complex and polygenic in nature [14] [15] [16] [17] .
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Epigenetic modulation of gene expression as a result of varying environmental exposure is also known to influ ence disease risk 18 . Numerous posttranslational mech anisms that are activated in response to environmental factors have also been implicated in the development of cardiovascular diseases 19 . Short of cloning the patient or their heart, primary cardiovascular cells (such as cardio myocytes, endothelial cells [ECs] , and smooth muscle cells [SMCs] ) containing the same genetic landscape and environmental exposure as the patient might arguably serve as the nextbest predictive model of disease risk. However, the procurement of primary cardiovascular cells, especially adult cardiomyocytes, requires invasive manoeuvres that carry substantial risks. Furthermore, the longterm maintenance of quality primary cells in culture to allow prolonged in vitro investigation is not feasible. For these reasons, hiPSC technology is an attractive tool because it facilitates the generation of unlimited amounts of patientspecific cardiovascular cells that closely mimic their endogenous counterparts.
Aside from mimicking primary cardiovascular cells, hiPSCderived cardiovascular cells act as an 'integrator' in precision medicine. When exposed to environmental perturbation in vitro, hiPSCderived cardiovascular cells integrate the patient's genomic disease susceptibility with the environmental influence to produce a disease pheno type that simulates the patient's condition. Therefore, hiPSCderived cardiomyocytes (hiPSCCMs) can poten tially be used in a patient with unknown cardiomyo pathy or lifethreatening arrhythmia to assess whether a variant of unknown significance on genetic testing is diseasecausing. The same technique can also be per formed to understand why a patient with familial dilated cardiomyopathy has a much more severe clinical pheno type than a sibling who has the same genetic mutation in the cardiac troponin T gene, but has only a mild clinical phenotype. The use of hiPSCCMs in this setting can also be extended to predict whether exposure to certain antipsychotic medications would trigger druginduced lifethreatening arrhythmia, as hiPSCCMs can be chal lenged with adrenergic stress to further elicit the dis ease phenotypes. Therefore, the potential applications for hiPSCs in precision medicine are enormous, and findings obtained from hiPSCbased interrogation can complement other existing clinical diagnostic tools to guide the practice of precision medicine.
Advances in hiPSC technology
Numerous technical advances have been made in the field of hiPSCs, including refined protocols for hiPSC reprogramming and hiPSC differentiation into cardio myocytes, ECs, and SMCs 7, [20] [21] [22] . These protocols have opened the door for many exciting hiPSC applica tions, including disease modelling, drug screening, and regener ative therapy. This Review will focus on the first two applications; hiPSCbased regenerative therapy has been discussed in previous publications 23, 24 . hiPSC technology has evolved rapidly since the initial discovery made by Yamanaka and colleagues that human fibroblasts can be reprogrammed by overexpressing four different transcription factors: octamerbinding protein 3/4 (OCT 3/4; also known as POU5F1), SOX2, Myc protooncogene protein (cMYC), and Krüppellike factor 4 (KLF4) 25 . This reprogramming technique was also reproduced by other groups using either the same or different variants of the factors used by Yamanaka and colleagues [26] [27] [28] . Similarly to human embryonic stem cells (hESCs), hiPSCs derived from somatic cell sources show unlimited selfrenewal and pluripotency, characterized by their capacity to differentiate into cells of all three germ layers. However, unlike hESCs, the generation of hiPSCs does not require human embryos and thus raises fewer ethical concerns, which have hindered the pro gress of hESC research in the past. Furthermore, hiPSC derivatives from different patients confer patientspecific phenotypes owing to their unique genomic landscapes. The patientspecific hiPSC derivatives therefore serve as ideal platforms not only for modelling monogenic and polygenic diseases in cell culture, but also for conducting drug discovery on a realworld patient population with diverse genetic backgrounds.
Reprogramming methods
Since Yamanaka's seminal research on mouse iPSCs 29 and hiPSCs 25 , for which he received the Nobel Prize in Physiology or Medicine in 2012, there have been continu ing efforts to make the reprogramming process safer and more efficient. Integrating retroviral or lentiviral vectors that were initially used for reprogramming could cause insertional mutagenesis 30 , and the retained expres sion or reactivation of a reprogramming factor such as cMYC could be tumourigenic 31 . Given these concerns, non integrating viral vectors (such as Sendai virus 32 , Adenovirus 33 , and Epstein-Barr virus 26 ), non viral vectors (such as plasmids 34 , minicircles 35 , and codon optimized miniintronic plasmid 36 ), excisable integrating vectors (including Cre-recombinasebased 37 and piggyBac transposonbased 38 ), synthetic modified mRNAs 39 , and pluripotency proteins 40 have all been explored as safer alternatives for the generation of hiPSCs. The choice of reprogramming strategies, however, depends on the downstream applications desired and should be carefully considered to balance factors such as reprogramming effi ciency, amounts of residual transgene retention, rates of
Key points
• Human induced pluripotent stem cells (hiPSCs) can now be reprogrammed from different somatic cell sources and differentiated into common cardiovascular cell types, including cardiomyocytes, endothelial cells, and vascular smooth muscle cells • hiPSC-derived cardiovascular cells recapitulate patient-specific and disease-specific phenotypes, which can be exploited to design individualized treatment strategies • hiPSC derivatives have enabled the accurate modelling of numerous cardiovascular diseases, including cardiomyopathies, arrhythmia syndromes, cardiometabolic disorders, vascular diseases, and valvulopathies • hiPSC-based platforms for drug discovery and cardiotoxicity testing are now being incorporated into major pharmaceutical drug development pipelines and standards of drug safety testing, respectively • Further refinement in large-scale production of mature hiPSC-derived cardiovascular cells will be necessary to realize the potential of using hiPSCs to guide precision medicine aneuploidy, cost, and required workload 41 . Importantly, although the reprogramming process can potentially introduce genetic variation to produce undesir able pheno types for the hiPSCs or their derivatives, most of the genetic vari ations found in the hiPSC derivatives can be traced to those variations already existing in the somatic source cells 42 . Similarly, the epigenetic variations found in hiPSCs are attributable to the genetic background of the source cells rather than the reprogramming process 43 .
Cardiomyocyte differentiation
The protocols for generating hiPSC derivatives were derived from early hESC research. Initial efforts to differ entiate hPSCs into cardiomyocytes focused mainly on the use of embryoid bodies (EBs). Inductive strategies using cocultures of hESCs and mouse visceral endoderm like (END2) cells were also explored, but were found to be relatively inefficient 44 . For EBmediated differenti ation, the hESCs grown on irradiated mouse embryonic fibroblasts were dispersed and cultured in suspension, where spontaneous cell aggregates (EBs) formed 45, 46 . After plating, cardiomyocytes from contracting EBs could be separated out and used for subsequent analy sis and manipulation. The EBderived cardiomyocytes resembled earlystage cardiomyocytes in terms of myofibrillar organization, gene expression pattern, and chronotropic responses to catecholamines. Similar differ entiation protocols were later validated for hiPSCCMs, which were structurally and electrophysio logically indistinguishable from hESCderived cardio myocytes (hESCCMs) 47 . The major problems with early EBbased protocols were their low efficiency and considerable linetoline variability as a result of heterogeneous EB sizes. For these reasons, EBbased protocols were modi fied to include 'forced aggregation' strat egies 48 . In these modified protocols, a defined number of enzymatically adapted hESCs or hiPSCs were placed in Ubottomed or Vbottomed wells and subjected to centri fugation. These manoeuvres led to aggregates of uniform sizes that were more conducive to consistent cardiac differentiation. The precise modulation of meso dermal induction, fol lowed by early cardiac differentiation, was achieved by the timely introduction and removal of growth factors that influenced four major signalling pathways in nor mal cardiac development: the bone morpho genetic pro tein (BMP) pathway, the transforming growth factorβ (TGFβ)/activin/Nodal pathway, the Wnt pathway, and the fibroblast growth factor (FGF) pathway 20 . Dubois and colleagues were able to differentiate hESCs into cardiomyocytes of up to 98% purity using an EBbased approach with sequential addition of multiple growth factors (that is, BMP4, activin A, FGF2, vascular endothelial growth factor [VEGF] , and Dickkopfrelated protein1 [DKK1]), followed by flow cytometrybased purification against a novel cardiac specific cell surface maker, signalregulatory protein α (SIRPA) 49 . Successful differentiation of hESCs into cardio myocytes was con firmed by assessing both cardiac troponin T (cTnT) posi tivity on flow cytometry and confirmatory expression of cardiac markers including NK2 homeobox 5 (NKX2.5), myosin heavy chain (MYH) 6, MYH7, and myosin light chain 7 (REF. 49 ). However, owing to the technically com plex and labourintensive nature of EBbased protocols, the monolayerbased cardiac differentiation method has become more widely used.
Laflamme et al. cultured hESCs as monolayers and induced cardiac differentiation with sequential addi tion and subsequent removal of activin A and BMP4, such that they were able to obtain cultures of up to 30% pure cardiomyocytes 50 . Subsequently, other versions of the monolayer approach using additional growth fac tors such as Wnt3a, DKK1, FGF2, or Wnt inhibitors were found to be more effective [51] [52] [53] Wnt inhibitors to produce contractile sheets of >95% pure cardiomyocytes from 11 hiPSC lines 55 . Collectively, these studies show that chemicallydefined protocols are both efficient and costeffective for largescale de novo production of functional cardiomyocytes. The differentiation efficiency for either cell type was as high as 30% by day 10 of differentiation. More impor tantly, these cells formed primary vascular plexus upon coculture. Ferreira et al. also showed the possibility of isolating CD34 vascular progenitor cells from EB sus pension and differentiating them into both ECs using endothelial growth medium2 (EGM2) supplemented with VEGF, and SMCs using EGM2 supplemented with plateletderived growth factor (PDGF) 58 . The resultant cells expressed characteristic cell type specific markers and functionally contributed to formation of the micro vasculature after their implantation into mice. This proto col was subsequently refined to include cocultures of hESCs and OP9 stroma cells in a medium supplemented with VEGF, FGF2, and BMP4 to generate CD31 + CD34 + vascular progenitor cells 59 . These cells were then further differentiated into ECs using EGM2 medium supple mented with VEGF, or into SMCs using SMC prolifer ation media supplemented with PDGF, followed by SMC differentiation medium supplemented with TGFβ1 (REF. 59 ). The resultant yields of ECs and SMCs were 10fold to 100fold greater than those obtained from the previous version of the protocol. As with cardiomyocyte differentiation, further optimization of these protocols is likely to include the use of monolayers of hiPSCs in serumfree, chemically defined media supplemented with small molecules to achieve improved simplicity, convenience, costeffectiveness, and efficiency.
Differentiation of ECs and SMCs

Disease modelling with hiPSC derivatives
The practice of precision cardiovascular medicine requires a solid understanding of why some patients with particular genetic mutations or single nucleotide polymorphisms are at increased risk of developing complications, and why other patients with the same genetic alteration respond differently to the same clin ical treatment. These fundamental questions can be fully answered only with a clear comprehension of the differ ent disease processes at the molecular or cellular level. hiPSC technology has allowed researchers to efficiently produce human cells with specific patient and disease characteristics. Extensive efforts are now devoted to modelling various cardiovascular diseases using hiPSC derivatives with the hope of understanding mechan istically how patients' genotypes are related to their cellu lar phenotypes. .
Arrhythmias and channelopathies
Early attempts at using hiPSCCMs to model cardiovas cular diseases focused on arrhythmic syndromes and channelopathies because of their clear, distinct, and easily assessable phenotypes both clinically and in cell culture. Of these, familial long QT syndrome (LQTS) and catecho laminergic polymorphic ventricular tachycardia (CPVT) were the most commonly modelled diseases, aside from the very rare conditions of Jervell and Lange-Nielsen syndrome (JLNS) 63 and Timothy syndrome 80 .
Familial long QT syndromes. Familial LQTS is an arrhyth mic condition in which mutations in either the ion channel proteins or other proteins that participate in the formation of the cardiomyocyte's action potential cause prolongation of action potential duration (APD) and corresponding QT interval on a surface electrocardio gram 101 . The latter is associated with an increased risk of lifethreatening arrhythmia (such as torsade de pointes [TdP]). Using hiPSCCMs, investigators have modelled LQTS based on the premise that neither the traditional heterologous expression systems nor transgenic animal models can fully simulate diseased human cardiomyo cytes, owing to speciesdependent differences in the electrophysiological characteristics of cardiomyocytes 102 .
Moretti et al. first demonstrated the feasibility of modelling type 1 LQTS (LQT1) using hiPSCCMs from a patient with a missense mutation (R190Q) in the KCNQ1 gene 60 . This missense mutation was found to cause a trafficking defect in the K v 7.1 channel pro tein, leading to a 70% reduction in the slowly activating delayed rectifier potassium current (I Ks ), prolongation of APD, and an increase in arrhythmia with βadrenergic agonists in the diseased hiPSCCMs. Ma et al. subse quently showed that hiPSCCMs derived from a patient carrying a different KCNQ1 mutation (exon 7 del) not only faithfully recapitulated the patient's clinical pheno types, but also responded to ML277, a novel drug under development to treat arrhythmias 62 . Egashira et al. per formed electrophysiological tests on hiPSCCMs derived from a young survivor of sudden cardiac death (SCD) with clinical suspicion of LQT1 (REF. 61 ). A novel KCNQ1 mutation (1893delC) associated with a trafficking defect in K v 7.1 was identified, and thought to be the culprit of the patient's progressive clinical course. These findings together demonstrated the diagnostic and predictive potential of patientspecific hiPSCCMs despite their relatively immature ionchannel profile. Although I Ks is significantly reduced in hiPSCCMs compared with adult cardiomyocytes, these cells show repolarization reserve, an important concept explaining why some I Ks inhibitors alone do not cause appreciable APD prolong ation unless the rapidly activating delayed rectifier potassium current (I Kr ) is also compromised 103 . With further improvement in cardiomyocyte maturation protocols (for example, pacing methods), these cells will become even more robust for modelling LQT1 (REF. 104 ).
Type 2 LQTS (LQT2) is the second most common LQTS after LQT1. LQT2 is characterized by muta tions in the KCNH2 gene that result in disruption of the human Etheràgogorelated gene (hERG) potas sium channel and reduction in I Kr 101 . Itzhaki et al. first
reported that hiPSCCMs derived from a patient carry ing a A614V missense mutation in the KCNH2 gene had reduced I Kr , increased APD, early afterdepolarization, and triggering activities that were consistent with the patient's history of prolonged QT interval and TdP 65 . Matsa et al. further demonstrated that hiPSC CMs derived from an asymptomatic disease carrier of the G1681A mutation in the KCNH2 gene had only APD prolongation, but no catecholamineinduced early 
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afterdepolarizations, consistent with the patient's clin ical course 64 . In addition, allelespecific knockdown of the mutated mRNAs that left wildtype mRNAs intact rescued the LQT2 phenotype at the cellular level, fur ther confirming the dominantnegative effect of this particular mutation that is thought to impair hERG glycosylation, maturation, trafficking, and degrada tion 105 . These findings emphasized the importance of understanding the functional ramifications of differ ent genetic defects at the molecular and cellular levels so that novel, targeted therapeutics can be developed accordingly in a personalized manner. 
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Low lysosomal α-glucosidase activity, high glycogen content; phenotypes reversed with recombinant lysosomal α-glucosidase or l-carnitine 96 Exon 18del, 1441delT, c.G2237A . Collectively, these findings underscored the need to understand fully the functional consequences of a given mutation for the development of effective therapies. This need is particularly pertinent to CPVT and pre cision medicine because both of its subtypes (CPVT1 and CPVT2) have a similar clinical presentation, and yet their underlying Ca 2+ handling disturbances are dif ferent owing to their distinct mutations. Indeed, CPVT2 hiPSCCMs have significantly lower Ca 2+ buffering capacity (or caffeinemediated Ca 2+ release) than CPVT1 hiPSCCMs, owing to their mutated CASQ2 proteins, whereas CPVT1 hiPSCCMs have altered sensitivity to ryanodine owing to their mutated RyR2 proteins 78 . These functional differences are important and suggest that the treatment for patients with different CPVT subtypes will need to be individualized.
Familial cardiomyopathies
Modelling of cardiomyopathies using hiPSCCMs is considerably easier for familial cardiomyopathies than acquired cardiomyopathies because the disease causing gene mutations are known in most cases. Familial cardio myopathies, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and arrhythmo genic right ventricular cardiomyopathy (ARVC), will be specifically discussed in this section. . In a pioneering study, Sun et al. used hiPSCCMs to model the disease in a fam ily of seven patients spanning three generations, some of whom had a heterozygous point mutation (R173W) in the TNNT2 gene, while others served as controls 81 . Compared with control iPSCCMs, the diseased hiPSC CMs showed impaired Ca 2+ handling and reduced con tractility. Despite the immaturity of the derived hiPSC CMs, this study paved the way for a subsequent study by Wu et al., which demonstrated mechanistically that the mutated TNNT2 caused the cardiomyopathic pheno types by nuclear translocation, followed by epi genetic activation of the PDE2A and PDE3A genes, leading to contractile dysfunction 82 . These studies showed that mechanistic studies on patientspecific cardiomyocytes could be performed using hiPSC technology.
Familial DCM caused by mutations of other genes such as LMNA and DES have also been successfully modelled using hiPSCCMs 83, 84 . Most recently, DCM caused by mutations that truncate the massive sarco mere protein titin (TTNtvs) were modelled using hiPSC derived 3D cardiac microtissues, which had the advantage of generating more mature cardiac pheno types than a monolayer of hiPSCCMs 108 . In this study, patient derived cardiac microtissues with TTNtvs developed sarcomere insufficiency, impaired contrac tile response to mechanical or βadrenergic stress, as well as attenuated growth factor signalling activation. Interestingly, cardiac microtissues with Iband TTNtvs showed fewer contractile deficits than those with Aband TTNtvs because of differential splicing favour ing partial omission of the mutated Iband exons. This observation provides an explanation for why patients with DCMs and Iband TTNtvs tend to fare better clin ically than those with Aband TTNtvs. Here, hiPSC technology enables prognostication of titinrelated DCMs, an outcome that is consistent with the goals of precision medicine.
The hiPSCbased studies of DCM thus far serve as a great starting point for further investigation of this disease in a biologically relevant human cell culture model. Despite their relative immaturity, the diseased hiPSCCMs can recapitulate some clinical pheno types of the patients from which the cells were derived. Furthermore, the findings obtained from these cells should lead to moretestable hypotheses. Additional studies will be needed to confirm whether these cells can fully recapitulate every aspect of human DCM, as well as to potentiate full maturation of hiPSCCMs so they can best simulate adultonset cardiomyopathies.
Hypertrophic cardiomyopathy. HCM manifests clin ically as asymmetrical left ventricular hypertrophy with increased risks of heart failure and life threatening arrhythmia. In a seminal study, Lan et al. first showed the feasibility of modelling HCM using hiPSCCMs derived from a family of 10 individuals with an autosomal dominant missense MYH7 mutation (A663H) 85 . 86 . Furthermore, the investi gators added whole transcriptomesequencing results to implicate the potential roles of Wnt1, FGF, and Notch signalling pathways in the pathogenesis of HCM, some of which could serve as potential therapeutic targets for the treatment of HCM beyond βblockers and Ca 2+ channel blockers 86 .
Arrhythmogenic right ventricular cardiomyopathy.
ARVC is an inherited heart disease characterized by both fibrofatty infiltration and cardiomyocyte loss pre dominantly in the right ventricle and is associated with an increased risk of SCD 107 . Modelling ARVC has proved to be challenging because of its adultonset pheno type. This issue was addressed in a pioneering study by Kim et al., which showed that hiPSCCMs from patients with ARVC (homozygous c.2484C>T mutation in the desmosomal PKP2 gene) had abnormal plakoglobin nuclear translocation and decreased βcatenin activity in baseline cardiogenic conditions 89 . However, these hiPSCCMs did not recapitulate the pathological pheno types of arrhythmogenic dysplasia/ cardiomyopathy (for example, exaggerated lipogenesis, cardiomyocyte apop tosis, and substantial electrophysio logical disturbances) unless the diseased hiPSCCMs were metabolic ally matured using a lipogenic cocktail consisting of insu lin, dexamethasone, and 3isobutyl1 methilxantine with rosiglitazone and indomethacin added 89 . Ma et al. further demonstrated that hiPSCCMs derived from patients with a c.1841T>C PKP2 mutation needed to be exposed to adipogenic differentiation medium in order to develop substantial lipogenesis 90 . Subsequently, Asimaki et al. showed that iPSCCMs from patients with a PKP2 mutation could be used to complement a zebra fish model for high throughput screening of drugs that modulate aberrant trafficking of intercalated disc pro teins 109 . These studies confirmed the challenges involved with modelling adultonset diseases using immature hiPSCCMs and called for further efforts to develop methods to increase the structural and metabolic maturation of the hiPSCCMs. 111 . Patients with this condition have insufficient lysosomal αglucosidase activity, leading to increased accumulation of glycogen in the nerves and the heart, with the latter typically manifesting as cardio megaly, cardiomyopathy, and arrhythmia. The infantileonset form of the disease is more common, but less severe than the adultonset form. Huang et al. first showed that hiPSCCMs derived from patients with the infantile form of Pompe disease had reduced lyso somal αglucosidase activity, leading to increased glyco gen content, swollen mitochondrial cristae, increased autophagosomelike structures, and mitochondrial dysfunction manifested as lower oxygen consumption rate and extracellular acidification rate 96 . Raval et al. provided additional mechanistic insight by showing that hiPSCCMs from the infantile onset form of Pompe disease had Golgibased glycosylation defects, which can potentially increase membrane Ca 2+ permeability and stimulate downstream hypertrophic signalling 97 . Importantly, these hiPSCbased disease models also enabled the screening of drugs (such as l carnitine) that could serve as effective adjuncts or alternatives to enzyme replacement therapy for Pompe disease 96 .
Cardiometabolic disorders
Mitochondrial aldehyde dehydrogenase 2 deficiency.
ALDH2 deficiency is commonly seen in Asian individ uals, and can be easily appreciated in social encoun ters that involve alcohol ingestion. Individuals with an ALDH2*2 polymorphism (E487K) have reduced ALDH2 enzyme activity, which leads to facial flush ing upon alcohol ingestion 94 . This polymorphism has also been linked to increased risk of coronary artery disease 112 and diabetes mellitusassociated complica tions 113 . Ebert et al. first used hiPSCCMs derived from a cohort of sexmatched East Asian individuals carrying this poly morphism to show that these cells were more susceptible to oxidative stress and apoptosis that were secondary to toxic aldehyde buildup during ischae mic injury 94 . These effects were mediated by reactive oxygen species (ROS)mediated upregulation of cJun Nterminal kinase 1 (JNK1; also known as MAPK8), such that administration of a JNK inhibitor restored ROS levels to baseline levels, as well as viability after ischaemia. This study was the first to use hiPSCs to investigate a genetic poly morphism with a strong ethnic prevalence. Such studies will allow for better eluci dation of the roles of ethnicity in the development and progression of cardiovascular diseases.
Diabetic cardiomyopathy. Diabetic cardiomyopathy, a longterm complication in patients with diabetes, was recently modelled by Drawnel et al. 93 hiPSCCMs from healthy donors were metabolically matured with insulin and fatty acid supplementation in the absence of glucose to simulate adult metabolism. After expo sure to a diabetomimetic medium, the hiPSCCMs developed phenotypes of diabetic cardiomyopathy characterized by cellular hypertrophy, upregulation of hypertrophic genes, increased release of Btype natri uretic peptide, myofilament disarray, and lipid accumu lation and peroxi dation. By contrast, the hiPSCCMs derived from patients with type 2 diabetes developed similar pathological phenotypes in the absence of the diabetomimetic medium. These results showed a genetic component in the development of diabetic cardiomyopathy, given that the diseased hiPSCCMs behaved differently at baseline compared with normal hiPSCCMs. Therefore, many other cardiomyopathies thought to be acquired (for example, chemotherapy induced cardiomyopathy 114 , alcoholic cardiomyopathy, and viral cardio myopathy 100 ) could conceivably also have a genetic component, warranting further study using hiPSCCMs.
Diseases affecting ECs or vascular SMCs
In addition to diseases affecting cardiomyocytes, many diseases that affect ECs or vascular SMCs are also ideal targets for hiPSC modelling for several reasons 115 . First, there are speciesdependent differences in the character istics and functions of ECs and SMCs, which make animal models alone insufficient to capture dis ease phenotypes fully. Secondly, there is limited access to primary ECs and SMCs owing to the invasive nature of the isolation procedures. Finally, primary ECs and SMCs lose their primary phenotypes after longterm cell culture. For these reasons, the limitless supply of patientspecific and diseasespecific ECs and SMCs afforded by hiPSC technology greatly facilitates the assessment of ECrelated and SMCrelated diseases in cell culture. 117 . In both conditions, ELN mutations are thought to disinhibit SMC proliferation and cause arterial stenosis.
Williams
Ge et al. first derived hiPSCSMCs from a patient with a fournucleotide insertion mutation in exon 9 of ELN and showed that these cells had fewer organized networks of smooth muscle α actin filament bundles, conferring a less mature phenotype and increased prolifer ation rates 118 . These pathological features were rescued by elastin recombinant protein, thus confirm ing elastin haploinsufficiency as the cause. Subsequently, hiPSC SMCs derived from patients with WBS were found to have the same pathological features that were later confirmed by Kinnear et al. 119 . The use of hiPSC in this context was an important breakthrough, because hemizygous transgenic mouse models of WBS did not develop supravalvular aortic stenosis 120 . Importantly, the researchers found the drug rapamycin, an anti proliferative agent, to be effective at reversing the pathological phenotypes, demonstrating the potential use of this FDAapproved drug for the prevention of arterial stenosis after surgical correction.
Calcific aortic valve disease in association with con genital bicuspid valve. Calcific aortic valve disease is the underlying indication for >50,000 aortic valve replace ments every year in the USA 121 . Approximately half of all cases of aortic stenosis leading to aortic valve replace ment in adults are due to congenital bicuspid valve, which occurs in 1-2% of the population 122 . In individ uals with congenital bicuspid valve, the aortic side of the valve is associated with reduced shear stress, increased calcification, and downregulation of NOTCH1 signal ling, whereas the ventricular side of the valve is linked to increased shear stress, reduced calcification, and upregu lated NOTCH1 signalling [123] [124] [125] . Theodoris et al. derived hiPSCECs from three patients with calcific aortic valve disease secondary to congenital bicuspid valve who had a nonsense heterozygous mutation (N1) leading to NOTCH1 haploinsufficiency 126 . Under increased shear stress, this NOTCH signalling defect led to epigenetic dysregulation and subsequent aberrant upregulation of proosteogenic and inflammatory signalling in these cells, consistent with the clinical observation of more calcification and inflammation on the aortic side of the valve. This study demonstrated that hiPSCECs could recapitulate the clinical phenotype of the disease and emphasized the need to evaluate endothelial biology under conditions of shear stress.
Hutchinson-Gilford progeria syndrome. HutchinsonGilford progeria syndrome (HGPS) is a genetic condi tion characterized by premature ageing that begins in childhood 127 . A single point mutation in the LMNA gene, leading to the formation of progerin, a truncated splic ing mutant of the nuclear protein lamin A, is thought to underlie this condition. Indeed, hiPSCSMCs taken from patients with HGPS had a premature senes cence phenotype associated with vascular ageing, and character ized by increased senescenceassociatedβGal staining, reduced telomere length, reduced number of Ki67positive cells, and compromised cell prolifer ation 128 . Progerin was shown to downregulate DNA dependent protein kinase catalytic subunit expression, which served as a marker for premature vascular ageing. In another study, fewer hiPSCderived mesen chymal stem cells (hiPSCMSCs) survived compared with con trol hiPSCMSCs under conditions of starvation and hypoxia, suggesting that perhaps progerin exerted its pathological effects through inhibiting the stem cell pool in the vascular compartment 129 . These results high lighted the utility of differentiating hiPSCs into multiple cell types within the vasculature so that the contrib ution from each cell type to the vascular condition can be isolated and identified.
Genome-editing strategies
Most of the aforementioned studies used hiPSC deriv atives from healthy patients or nonaffected relatives of patients with the disease as negative controls. However, the genetic landscapes of the control hiPSCs and the dis eased hiPSCs are not equivalent beyond the mutations of interest, and these differences could easily confound the study findings. For these reasons, genomeediting strategies that employ zincfinger nucleases (ZFNs), transcription activatorlike effector nucleases (TALENs), or clustered regulatory interspaced short palindromic repeat (CRISPR)/Casbased RNAguided DNA endo nucleases have been employed to create isogenic con trols from the diseased lines 130, 131 . Alternatively, a specific mutation can be introduced into a normal hiPSC line to create a diseased line in cell culture, bypassing the need to recruit patients with the same mutation -a task that can be very challenging for rare genetic disorders. Phenotypic rescue after correction of the mutation can then help to confirm the contribution of the mutation to the diseased phenotype.
Karakikes et al. demonstrated the use of TALEN mediated homologydirected repair in hiPSCCMs derived from a patient with p.R14del mutation in the phospholamban gene (PLN) 132 . Upon differentiation, Ca 2+ handling abnormalities and abnormal cytoplas mic distribution of PLN, characteristic of DCM, were evident in the patientderived hiPSCCMs. These dis ease phenotypes were rescued in the TALENcorrected hiPSCCMs, further confirming the causal relationship between the mutation and the DCM phenotypes. In a separate study, Wang et al. successfully used ZFNs to create diseased hiPSCCMs carrying LQT1 (KCNQ1) and LQT2 (KCNH2) mutations from wildtype control hiPSCCMs. These mutated lines had prolonged APDs compared with isogenic controls, consistent with the expected LQTS phenotypes 133 . These approaches for studying the contributions of a specific gene muta tion are expected to become more popular owing to the difficulties in gaining access to patients with rare genetic diseases. Ultimately, understanding the effect of each gene mutation or polymorphism in individual patients will be the first step towards develop ing tailored therapies in the practice of precision medicine.
Drug discovery using hiPSC platforms
The advent of hiPSC technology has made it possible to pursue preclinical drug testing and discovery in a manner that substantially deviates from traditional platforms, namely, animal disease models and hetero logous expression systems. This new platform has been supported by both researchers and pharmaceutical com panies, who have been frustrated with the inability to deliver new, safe, and efficacious medications to address unmet medical needs. As hiPSC technology contin ues to improve, many hiPSC platforms are now being incorpor ated into the standards for drug safety testing and major pharmaceutical drugdevelopment pipelines.
Cardiotoxicity testing
Cardiotoxicity, such as druginduced QT prolongation, can cause lifethreatening arrhythmia (for example, TdP) and is the most common reason for latestage drug attrition and market withdrawal 134 . In 2005, the International Conference on Harmonization (ICH) issued a guidance document (E14), which mandated that all new drugs must undergo a dedicated electro cardiogram study in healthy volunteers called the Thorough QT/QTc (TQT) study 135 . Since its imple mentation, TdP has not been observed with any drugs with negative TQT results. However, the TQT study is costly and has been criticized for its low speci ficity, as it was responsible for the withdrawal of many efficacious QTprolonging drugs that were actually not proarrhythmic.
In its S7B guidance document, the ICH likewise required nonclinical assessment of a drug's arrhythmo genic potential using both the hERG assay and a non rodent QT interval study 135 . The hERG assay assesses a compound's capacity to block the hERG current (I Kr ) in transformed cell lines that overexpress hERG, namely Chinese hamster ovary (CHO) cells or human embryo nic kidney (HEK) cells, even though they have largely different ionchannel profiles from adult human cardio myocytes. In an effort to make cardiotoxicity testing more biologically relevant, the FDAsponsored Cardiac Safety Research Consortium and the notfor profit Health and Environmental Sciences Institute have recommended, as a part of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, to include both in silico computational modelling and hiPSCCMs into the nonclinical drug cardiotoxicity assessment 136 . Computer simulations that incorporate experimentally determined behaviours of multiple ion channels have been shown to predict clinical risks of arrhythmia better than the hERG assay 137 . Likewise, hiPSCCMs have been validated for their capacity to recapitulate the electro physiological phenotypes of many genetic arrhyth mic disorders 101 . Compared with in silico modelling, hiPSC CMs can provide information on proarrhythmia potential in addition to the long QT phenotype.
For drug toxicity testing, multielectrode array has been validated for detecting druginduced arrhythmia on hiPSCCMs based on field potential recordings 138 . The impedancebased platforms also offer assessment of cardiotoxicity by characterizing parameters related to the beating of cardiomyocytes 139 . Guo et al. used such platform to assess the beating rate and amplitude of hiPSCCMs exposed to different classes of cardioactive compounds and found that these cells developed the expected responses based on their known pharmaco logical actions 140 . Interestingly, arrhythmia induced by terfenadine, a drug known for torsadogenicity, was observed only after extended drug treatment and monitor ing. Importantly, this platform could be used to differentiate between torsadogenic drugs and those that prolonged QT, but did not cause TdP. A human cardio myocyte arrhythmic risk model based on this plat form, incorporating parameters such as drug induced arrhythmic beating and change in beating rate, and the known effective serum therapeutic concentration of each drug, provided better predictability of torsado genicity in humans than either the hERG assay or clinically observed QT prolongation 141 . In contrast to the electrodebased techniques, Sirenko et al. used timelapsed fluorescence imaging in conjunction with fluorescent dyes to screen drugs for their effects on both viability and Ca 2+ influx patterns that are characteristic of known ionchannel block ers 142 . A scaledup version of this system incorporating the Toxicological Prioritization Index for data analysis enabled the effective ranking of numerous drugs in terms of cardiotoxicity 143 . However, the use of fluores cent labels in this platform increased the potential for both phototoxicity and undesirable interactions between the labels and the test compounds, and these effects had to be carefully excluded before cardiotoxicity could be fairly interpreted.
A labelfree videobased platform that captures and analyses the beating patterns of cardiomyocytes has recently been developed to assess cardio toxicity by measur ing changes in beat rate and duration, and identifying contractile arrhythmia 144 . The major advantages of this system include its compatibility with standard multiwell plates, sterility, and its labelfree, noninvasive nature. Furthermore, drug effects can be easily interrogated longitudinally without any compro mise to cell integrity. However, the system is limited by the time lag between video capture from one well to the next, which makes studying fast drug responses challenging. Further optimization of this platform should include a microfluidic drug delivery system to allow the analysis of fast drug responses. Ultimately, a multimodal tool optimized to simultaneously assess morphology, contractility, arrhythmia, biosynthetic function, and metabolism will be the ideal platform for drug developers (FIG. 2) .
Compared with the high costs associated with animal experiments 145 , hiPSCbased drugdiscovery platforms can produce highquality drugs at a relatively low cost. Savings of up to US$100 million per drug development process and a reduction in attrition rate (currently at 10%) can be achieved with hiPSC tech nologies 146 . In addition, the use of chemically defined media, instead of commercial media, can reduce the cost of hiPSC culture and cardiac differentiation by as much as 75% 147 . These advantages provide a further financial impetus to develop a hiPSCbased platform for drug development.
Predicting clinical drug responses
For hiPSC technology to deliver its great promises for precision medicine, it is important to consider how well patientspecific hiPSC derivatives can recapitulate the Nature Reviews | Cardiology 148 . The hiPSCCMs derived from the 17 patients who experienced severe QT prolongation in response to sotalol also had corresponding extreme measures of APD. LQTrelated arrhythmias were observed in hiPSC CMs derived from five of seven patients with the most severe responses to sotalol clinically. These results provided some initial evidence that hiPSCCMs could accurately predict clinical drug response and warranted increased incorporation of hiPSCCMs into the early stages of clinical trials so that more data regarding their predictability of cardiotoxicity could be gathered 10 .
Since the initial discovery of hiPSC technology, some drugs that have been developed through the hiPSC platform are now making their appearance in clinical trials, mainly related to neurological dis eases 149 . Indeed, in the field of Alzheimer disease, BMS986168, a tauspecific antibody, is now under going phase I toxicity testing in healthy volunteers after initial development through the use of hiPSCderived cortical neurons 150 . Retigabine, an FDAapproved anti convulsant drug that can suppress the hyperexcitable phenotypes of different hiPSC models of amyotrophic lateral sclerosis is being assessed in a phase II trial, bypassing further animal model validations 151 . These trials offer valu able insights into how well the hiPSC derivatives can predict patientspecific drug responses, and highlight an important niche for the hiPSCbased platforms in drug repurposing.
Tissue engineering for drug development Advances in tissue engineering and microfabrica tion have provided additional avenues for advancing hiPSCbased strategies for drug development. Various research groups have demonstrated the utility of a 3D hiPSC culture to improve simulation of adult cardiac tissue compared with a 2D monolayer of hiPSCs. In a pioneering study, Eschenhagen et al. developed a 3D model of contracting heart tissue by culturing embry onic chick cardiomyocytes in a collagen matrix 152 . Later refinement of this technique included changing colla gen to fibrin for faster polymerization and more uni form cell distribution, introduction of elastic silicone posts to allow physiological auxotonic contraction, and adaptation to a standard 24well format suitable for drug screening 153 . These 3D cardiac tissues have Comparing models of arrhythmia risk Before the development of hiPSC technology, numer ous cellular, multicellular, isolated perfused heart, and animal models had been used to predict druginduced arrhythmia risks in humans. An allpurpose equiva lent for proarrhythmia risk assessment does not exist, because each model has its own advantages and dis advantages, and each captures only a partial aspect of proarrhythmia in humans. For example, the hERG assay has been popular with most early drug development programmes because of its simplicity, low cost, high sen sitivity, and potential for mediumtohigh throughput when coupled with automated electrophysio logical or noninvasive fluorescence based platforms 160 . However, the assay is limited by low specificity, because some drugs can modulate arrhythmia risks by interacting with ion channels other than hERG, thereby generating either false positive results (as seen with verapamil) or falsenegative outcomes (as seen with afluzosin) 9, 161 . The hERG assay is also encumbered by a lack of standard ization, in that the halfmaximal inhibitory concen tration (IC 50 ) determination often varies substantially between laboratories, depending on protocolrelated parameters such as temperature, cell type, and the actual bath drug concentration 161 . Furthermore, owing to its singlecell nature, the hERG assay misses tissuelevel contribution to TdP (such as spatial dispersion of repolarization), which can be better interrogated with multicellular preparations such as the arterial perfused wedge prepar ations. However, these tissue preparations are themselves low throughput and vulnerable to selec tion bias, depending on from where in the heart the tissue slab was prepared 162 . This issue can be addressed using a Langendorffperfused heart model, which allows interrogation of monophasic action potential measurements both transmurally and around the ven tricles 163 . Moreover, repolarization abnormalities such as monophasic APD prolongation, triangulation, instabil ity, and reverse use dependence can serve as additional markers for proarrhythmia 164 . The common drawback of all in vitro models discussed above is the exclusion of neurohormonal and metabolic influences, which are known to modulate arrhythmia risks and can be studied only in intact animal models.
Animal models including rodents, rabbits, dogs, and pigs have all been used to predict druginduced arrhythmia. Rodent models are generally less rele vant than largeanimal models, owing to differences in molecular and cellular electrophysiology (heart rate, APD, ionchannel expression profile, and Ca 2+ handling properties), similar aspects of which are more commonly shared by large animals and humans 101 . Nonrodent models, however, incur greater costs and have their own welldescribed limitations 165 . For exam ple, the methoxaminesensitized anaesthetized rabbit model relies on the use of α 1 adrenergic stimulation to produce an increase in intracellular Ca 2+ concen tration, which predisposes the myocardium to drug induced arrhythmia. Although sensitive, the need for anaesthesia alters autonomic tone and influences myocardial electrophysiology. By contrast, the chronic atrio ventricular block canine (or nonhuman primate) model does not require anaesthesia, but relies on chronic myocardial adaptation to artificially introduced third degree atrioventricular block to generate suscep tibility to arrhythmia. However, because most patients with druginduced TdP do not have thirddegree atrio ventricular block, such a model, although more accurate in predicting the effects of many known torsadogens, might have limited predictability for patients with other underlying disease conditions.
The main advantages of using the hiPSCbased cell model for assessing proarrhythmia are numerous. First, compared with the CHO and HEK cells used in the con ventional hERG assay, hiPSCCMs retain the complex ity of human action potential generation by expressing important ion channels that modulate pro arrhythmia risks beyond just hERG. Second, hiPSCCMs can be derived from patients with varying underlying dis ease conditions, thus enabling the investigation of diseasespecific susceptibility to druginduced arrhyth mia. Finally, genome editing of hiPSCCMs with specific poly morphisms or mutations can be readily performed to examine their precise contribution to arrhythmia risks. As druginduced arrhythmia is influenced by multiple risk factors (including genetic predisposition, female sex, and presence of structural heart disease) 134 , hiPSCbased platforms allow many of these risk factors to be mechanistically investigated at the cellular level. However, hiPSCCMs are useful only as a cellular model. Mechanisms or modulating factors that can be better interrogated at the tissue, organ, or organism levels (for example, spatial dispersion of repolarization, and auto nomic, metabolic, adrenergic modulation) cannot be captured with hiPSCbased platforms. Further studies will be needed to determine how they can complement largeanimal models to constitute a complete assessment of proarrhythmia before human cardiotoxicity testing.
Challenges and future directions
In this Review, we have alluded on several occasions to one of the major limitations of hiPSC technology -the immaturity of hiPSC derivatives. For example, compared with adult cardiomyocytes, hiPSCCMs appear rounder, have fewer mitochondria, and have less organized sarcomeres 166, 167 . The geneexpression profiles, especially those of contractile proteins, simulate fetal cardiomyocytes 168 . Furthermore, the hiPSCCMs have poorly developed SR and altered Ca 2+ handling at early stages of differenti ation 169 , nonexistent transverse tubules 170 , automaticity 171 , and preference for glucose metabolism over fatty acid metabolism 172 , which are all consistent with immature phenotypes. Although vari ous maturation techniques (such as electro mechanical stimulation 157, 173 , overexpression of cardiac genes 104 or microRNA499 (REF. 174 ), exposure to fatty acid supple mentation 93 , and incorporation of cardiomyocytes into 3D tissue constructs 108 ) have all been attempted with varying degrees of success, it is unclear whether the most mature hiPSCCMs developed in an artificial cell culture environment can achieve the same level of maturity as adult cardiomyocytes in vivo. However, whether hiPSCCMs can have a substantial role in pre cision medicine depends on their as yet undetermined capacity to be used to predict accurately the clinical pheno types in some or all cases that other existing animal or cellular models cannot. The reports that most hiPSCbased models of genetic disorders seem to show clinically expected character istics are encourag ing. Nevertheless, morefocused studies incorporating hiPSCs in clin ical trials to correlate patients' hiPSCCMs and clinical phenotypes will be necessary to improve confidence in this technology 10 . A second major issue concerning hiPSC research is the heterogeneity of hiPSC lines and the cells derived from them. Owing to the clonal nature and low effi ciency of hiPSC derivation, considerable clonetoclone variations might exist because of varying genetic and epigenetic influences from individual somatic donor cells 42 . Furthermore, aneuploidy or subchromosomal variations accumulated during the reprogramming process can lead to varying differentiation capacity and resultant cellular phenotypes 42 . Even after differenti ation, the cell types derived are often a mixture of cells (such as atrial, ventricular, and nodal for cardiomyo cytes), which can further complicate the analysis. Given that most of the hiPSC studies thus far included only limited numbers of patientderived lines, the resultant conclusions, although mostly encouraging, need to be interpreted with care as the variations associated with the reprogramming and differentiation processes could be substantial. Selection of donor cells with the least accumulated mutations for reprogramming (young ver sus old) 42 , use of nonintegrating vectors for reprogram ming to avoid retention or reactivation of transgenes or insertional mutagenesis 41 , employment of differ entiation protocols that promote hiPSC homogeneity (EB with forced aggregation) 48 , and purification for the desired cell types (glucose deprivation for cardiomyo cytes) 172 are just some examples of efforts to reduce the heterogeneity inherent in the hiPSC platform. Ultimately, even with these efforts, the hiPSC lines could behave heterogeneously because of patient specific differences in genomics or epigenomics. Therefore, for an hiPSCbased investigation to be truly considered 'a trial in the dish' , hundreds of hiPSC lines will need to be generated to assess cardio toxicity fully over diverse genetic backgrounds. In this regard, the establishment of hiPSC repositories at different institutions to store patientderived hiPSCs along with the patients' clinical data will be crucial to carry out meaningful, largescale, hiPSCbased drug testing 175 . Lastly, for both precision medicine and largescale drug screening in the pharmaceutical industry, the chal lenge of how best to scale up the hiPSC platform to test tens to hundreds of hiPSC lines and drugs remains. The use of dynamic suspension cultures is a feasible solu tion for the derivation, expansion, and even differen tiation of hiPSCs into beating cardiomyocytes in either Erlenmeyer or spinner flasks 176, 177 . The hiPSC yield can be augmented by 25fold in 10 days, with retention of karyotype stability and pluripotency 178 . Coupled with the use of chemicallydefined media and small mol ecules instead of recombinant growth factors, such a platform can also reduce the cost dramatically, which is lower on a per cell basis than with adherent cell cul tures 179 . On an even larger scale, an automatic, modular robotic platform can be used for the highthroughput derivation, characterization, and differentiation of induced pluripotent stem cells 180 . Such a platform can reprogramme, expand, and characterize several hun dred hiPSC lines per month. More importantly, the system can reduce reagent cost by 5fold to 6fold, and increase productivity by 10fold to 12fold compared with previous automated systems that worked with a small number of lines at a time. Compared with manu ally selected hiPSC clones, the pooled polyclonal hiPSC lines derived from this automation had substantially less linetoline variation that is known to occur with manual hiPSC clone selection. With further refinement, such a system will not only enable largescale produc tion, characterization, and manipulation of iPSC lines, but will also ensure the experimental results are less prone to technical errors, which is necessary for the objective comparison of a large number of iPSC lines for both drug screening and phenotypic assessment in precision medicine.
Conclusions
The Precision Medicine Initiative emphasized the need to investigate further the functional importance of patients' genetic backgrounds. To this end, hiPSC technology has a unique role in its capacity to provide an unlimited supply of various cell types from patients, which otherwise would not be as easily obtained, cul tured, or studied. Among other achievements to date, patientspecific hiPSC derivatives have enabled the successful modelling of a number of cardiovascular dis orders that led to valuable new mechanistic insights and have contributed to comprehensive cardiotoxicity testing of drugs focusing on proarrhythmic potential instead of QT/APD prolongation alone. Finally, hiPSC technology can potentiate the development of drugs that can be tailored based on patientspecific differences at the cellular level.
As with any other experimental technique, there are fundamental limitations with hiPSCs, which might prevent the technology from completely replacing the existing experimental models or drugdiscovery meth ods, including clinical trials. As such, the predictability of hiPSCbased platforms will need to be better tested clin ically, so that their strengths and weaknesses can be better appreciated. Ultimately, if used in combination with the other existing approaches, we expect that the hiPSC based platforms will have a unique and prominent role in advancing the practice of precision medicine.
